Pentixapharm Holding AG (XTER:PTP) Current Accrued Expense: €0.00 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XTER:PTP Pentixapharm Holding AG XTER:PTP
19 GF Score
Price €1.91
! 1 Warning Sign
View Full Analysis

What is Pentixapharm Holding AG Current Accrued Expense?

Pentixapharm Holding AG XTER:PTP -0.78% 19 Current Accrued Expense is €0.00 Mil as of Jun. 2026. GuruFocus rates XTER:PTP with a GF Score™ of 19/100. The stock has 1 warning sign investors should review.

Pentixapharm Holding AG's Current Accrued Expense for the quarter that ended in Jun. 2026 was €0.00 Mil.

Pentixapharm Holding AG Current Accrued Expense Related Terms

Pentixapharm Holding AG Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for Pentixapharm Holding AG's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pentixapharm Holding AG Current Accrued Expense Chart

Pentixapharm Holding AG Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Current Accrued Expense
0.00 0.00 0.00 0.00 0.00

Pentixapharm Holding AG Quarterly Data
Dec21 Dec22 Dec23 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
XTER:PTP
19GF Score
Pentixapharm Holding AG XTER:PTP
Current Accrued Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pentixapharm Holding AG Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of €0.00 Mil mean?
Pentixapharm Holding AG (XTER:PTP) has a Current Accrued Expense of €0.00 Mil as of Jun. 2026. Current Accrued Expense records the total amount of accrued expenses. View historical data on Pentixapharm Holding AG and its competitors.
Is Pentixapharm Holding AG's Current Accrued Expense too high?
Pentixapharm Holding AG's current Current Accrued Expense is €0.00 Mil. Overall, Pentixapharm Holding AG has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Pentixapharm Holding AG's Current Accrued Expense compare to VRTX and REGN?
Pentixapharm Holding AG's Current Accrued Expense of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Biotechnology company?
A good Current Accrued Expense depends on the Biotechnology industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on Pentixapharm Holding AG and its competitors. Pentixapharm Holding AG's current Current Accrued Expense is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pentixapharm Holding AG stock overvalued right now?
Pentixapharm Holding AG (XTER:PTP) has a current Current Accrued Expense of €0.00 Mil. The current Current Accrued Expense is €0.00 Mil. Pentixapharm Holding AG's overall GF Score™ is 19/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For Pentixapharm Holding AG (XTER:PTP), the current Current Accrued Expense is €0.00 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Pentixapharm Holding AG Business Description

Other Exchanges PTPN:Austria
Address Robert-Rossle-Street 10, Berlin, DEU, 13125
Pentixapharm Holding AG is a clinical-stage biopharmaceutical company active in the field of research and development of radiopharmaceuticals for diagnostic and therapeutic applications. Radiopharmaceuticals are medical substances containing radioactive elements used in nuclear medicine to diagnose or treat diseases. Its clinical pipeline encompasses PentixaTher, a Yttrium-90 based therapeutic against non-Hodgkin lymphomas (NHL), and PentixaFor, a Gallium-68-based companion diagnostic. Its Pipeline products include: Pentixa Ther, PT-002, PentixaFor, PT-001, PentixaFor, PT-001, PT-00X, GT-001, GT-002, GT-005, GT-008, and GT-00X.
19GF Score

Get the complete analysis for XTER:PTP

Current Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.91
Price